COM701

Small molecule

CCompugen Ltd

COM701 is one of 32 small molecule programs targeting Ovarian Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerActive, not recruiting

Ovarian CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Hycamtin

MMeitheal

Phase 3

28 2

Perjeta

Roche

Phase 3

3 3

Aromasin

Pfizer

Phase 3

2 4

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

1 5

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

4 6

Chemotherapy Drug

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 7

Azenosertib

KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.

Phase 3

2 8

JSKN003

JJiangsu Alphamab Biopharmaceuticals Co., Ltd

Phase 3

1 9

Doxorubicin HCL Liposome

AAccelerated Community Oncology Research Network

Phase 3

2 10

In Vitro Sensitivity-Directed Chemotherapy

CChildren's Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Ovarian Cancer

NCT06888921

Clinical

Trials by Indication[1]

Advanced Solid Tumors2 trials

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Completed·CCompugen Ltd·Phase 1/2·NCT04570839·48 enrolled

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Completed·CCompugen Ltd·Phase 1·NCT03667716·121 enrolled

Ovarian Cancer1 trial

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

Recruiting·CCompugen Ltd·Phase 1/2·NCT06888921·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for COM701. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — COM701 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for COM701. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Compugen Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: CCompugen Ltd

COM701

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Advanced Solid Tumors2 trials

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News